explore -WSS

explore

author：hotspot 2025-09-28 18:20:53 - browse：3

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Why police arrested suspected Gilgo Beach killer away from his house

explore

WSS

NIH documents show early flaws of $1.6 billion long Covid program

Congress likely to miss an opportunity to fix drug shortages issue

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Let's speed up science by embracing open access publishing

knowledge

explore

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Everything to know for the next Powerball drawing as jackpot hits $1 billion

DIEP, the 'gold standard' of breast reconstruction, is under threat

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Guidelines to prevent youth baseball injuries need more muscle

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Federal judge rules Oregon’s tough new gun law is constitutional

hotspot

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Letters to First Opinion on caregivers, digital health, and more

With trial win, GSK could get blood cancer drug back on market

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

focus

focus

explore

entertainment